Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The current role of vigabatrin (Sabril (R)) in the treatment of epilepsies: Results of a consensus conference
Autore:
Schmidt, D; Brandl, U; Elger, CE; Kramer, G; Siemes, H; Stephani, U; Aksu, F; Boenigk, HE; Froscher, W; Keimer, R; Kluger, G; Kurlemann, G; Rochel, M; Schmitz, B; Stefan, H; Stodieck, S;
Titolo Testata:
AKTUELLE NEUROLOGIE
fascicolo: 10, volume: 27, anno: 2000,
pagine: 470 - 474
SICI:
0302-4350(200012)27:10<470:TCROV(>2.0.ZU;2-A
Fonte:
ISI
Lingua:
GER
Soggetto:
NEWLY-DIAGNOSED EPILEPSY; FIRST-LINE TREATMENT; GAMMA-VINYL GABA; INFANTILE SPASMS; VISUAL-FIELD; CARBAMAZEPINE MONOTHERAPY; ANTIEPILEPTIC DRUGS; TUBEROUS SCLEROSIS; CONSTRICTION; EFFICACY;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
27
Recensione:
Indirizzi per estratti:
Indirizzo: Schmidt, D Goethestr 5, D-14163 Berlin, Germany Goethestr 5 Berlin Germany D-14163 5, D-14163 Berlin, Germany
Citazione:
D. Schmidt et al., "The current role of vigabatrin (Sabril (R)) in the treatment of epilepsies: Results of a consensus conference", AKT NEUROL, 27(10), 2000, pp. 470-474

Abstract

The experience of recent years that treatment with vigabatrin may be associated with concentric visual field defects has led to a reevaluation of therisk-benefit ratio and to recommendations concerning the treatment of patients with epilepsy and to adequate safety monitoring. Despite the risk of visual field defects, vigabatrin is indicated for the adjunctive treatment of patients with difficult-to-treat partial epilepsy due to its otherwise good tolerability, good efficacy and favorable pharmacokinetics if drug resistance or intolerance has been shown with available alternative drug treatment and epilepsy surgery is not indicated or has been unsuccessful. Vigabatrin monotherapy continues to be a drug of first choice for the treatment of patients with West syndrome and has a positive risk-benefit ratio compared to other treatment options. Patients and their relatives have to be fully informed about the epilepsy and the risk-benefit ratio of vigabatrin including the mostly irreversible, usually concentric and mostly asymptomatic visual field defects. All patients - if they can be examined - should be examined by perimetry prior to and after 1-2 months of treatment with vigabatrin. In case of pathological visual fields treatment needs to be reevaluated. In case of normal perimetry another test should be done after 3-6 months, followed by 6 months intervals. All patients should be asked to inform their physicians in case of visual problems.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/04/20 alle ore 04:11:17